Showing 3131-3140 of 4063 results for "".
- Johnson & Johnson to Present New Data for Tecnis Odyssey at ASCRShttps://modernod.com/news/johnson-johnson-to-present-new-data-for-tecnis-odyssey-at-ascrs/2482753/Johnson & Johnson will present data supporting the performance of the next-generation Tecnis Odyssey IOL at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Los Angeles. J&J is featuring 22 company sponsored and investigator led studies
- Glaukos to Present Multiple Scientific Abstracts at ASCRShttps://modernod.com/news/glaukos-to-present-multiple-scientific-abstracts-at-ascrs/2482751/Glaukos announced that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 25-28, 2025 in Los Angeles. Glaukos will be exhibiting onsite at booth #2227. Glaukos is also spo
- MicroSurgical Technology (MST) to Discuss Advances in Vitrectomy Technology at ASCRShttps://modernod.com/news/microsurgical-technology-mst-to-discuss-advances-in-vitrectomy-technology-at-ascrs/2482749/MicroSurgical Technology (MST) announced it will share research during two presentations on the Vista 1-Step novel vitrectomy probe at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 25-28. The
- Sight Sciences Launches OMNI Edge Surgical System at ASCRShttps://modernod.com/news/sight-sciences-to-debut-omni-edge-surgical-system-at-ascrs/2482748/Sight Sciences announced the expansion of the OMNI product family by launching the OMNI Edge Surgical System. The new technology will debut at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, taking place April 25–27 in Los Angeles.<
- Neurotech Appoints Beth Marsh as Chief Commercial Officerhttps://modernod.com/news/neurotech-appoints-beth-marsh-as-chief-commercial-officer/2482746/Neurotech Pharmaceuticals announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Ms. Marsh will lead the commercial organization, including preparing for the US launch of Encelto (revakinagene taroretcel-lwey), the first and onl
- Zeiss to Showcase New Digital Technologies at ASCRShttps://modernod.com/news/zeiss-to-showcase-new-digital-technologies-at-ascrs/2482742/Zeiss Medical Technology will celebrate the adoption of digital cataract solutions and showcase newly available refractive treatment technology at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25–27 in Los Angeles. Zeiss marks a ma
- Atsena Granted FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy to Treat X-Linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-designation-gene-therapy-to-treat-x-linked-retinoschisis/2482737/Atsena Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid, to
- FDA Once Again Rejects Aldeyra's NDA of Reproxalap for Dry Eye Diseasehttps://modernod.com/news/fda-once-again-rejects-aldeyras-nda-of-reproxalap-for-dry-eye-disease/2482727/The FDA issued a complete response letter declining to approve Aldeyra Therapeutics' resubmitted new drug application (NDA) of reproxalap, an investigational drug candidate for the treatment of dry eye disease. Although no manufacturing or safety issues with repr
- Atsena Therapeutics Secures $150 Million to Advance Investigational Ocular Gene Therapyhttps://modernod.com/news/atsena-therapeutics-secures-150-million-to-advance-investigational-ocular-gene-therapy/2482726/Atsena Therapeutics has closed an oversubscribed $150 million Series C financing, which will be used to advance Atsena’s lead gene therapy program, ATSN-201, aimed at treating X-linked retinoschisis (XLRS). Additionally, the funds will support Atsena’s preclinic
- Maura Sweeney Appointed Chief Operating Officer at Lighthouse Guildhttps://modernod.com/news/maura-sweeney-appointed-chief-operating-officer-at-lighthouse-guild-1/2482720/Lighthouse Guild announces the appointment of Maura Sweeney as Chief Operating Officer, effective April 1, 2025. Ms. Sweeney has been a vital part of Lighthouse Guild since 2010, most recently serving as Chief Program and Services Officer. A seasoned health care professional, she brings